THE USE OF ANTIPLATELET DRUGS IN TREATMENT ACUTE MYOCARDIAL INFARCTION AT CAN THO GENERAL HOSPITAL IN 2021
Main Article Content
Abstract
Background: Acute myocardial infarction is the leading cause of death in the world. Acute myocardial infarction occurs when atherosclerotic plaque ruptures leading to thrombus formation. In order to effectively treat and prevent the risk of thrombosis, one of the first-choice drugs in the treatment of acute myocardial infarction are antiplatelet drugs. Therefore, the use of antiplatelet drugs in treatment of acute myocardial infarction is necessary. Objectives: Determining the rate of using antiplatelet drugs in the treatment of acute myocardial infarction. Materials and methods: A cross-sectional descriptive study with 380 acute myocardial infarction patients inpatient treatment at Can Tho General Hospital from 2021, January 1 to 2021, December 1. The patients in the study sample used antiplatelet drugs. Results: The rate of the group under 65 years old was 32.4%, the group aged 65 years and older was 67.6%. The mean age was 69 ± 12 years, the oldest was 96, the youngest was 23, of which a number of men accounted for 54.5%, women accounted for 45.5%. Antiplatelet drugs used in the treatment of acute myocardial infarction are aspirin, clopidogrel, and ticagrelor, accounting for 100%, 88.9% and 38.7% respectively. The starting dose rates for aspirin was 100%, clopidogrel was 88.9%, ticagrelor was 38.7% and the maintenance dose rate for aspirin was 100%, clopidogrel was 79.7%, ticagrelor was 38.7%. In addition, in the treatment of acute myocardial infarction, the combination of aspirin and clopidogrel was 88.9% and the combination of aspirin and ticagrelor was 38.7%. Conclusion: In the treatment of acute myocardial infarction, aspirin is used the most and is considered a drug first-line. The rate of aspirin use (100%) was higher than the rate of ticagrelor (38.7%). In addition, the ratio of the combination of aspirin and clopidogrel was higher than the ratio of the combination of aspirin and ticagrelor.
Article Details
Keywords
Acute myocardial infarction, Antiplatelet drugs, inpatient
References
2. Bộ Y tế (2020), Thực hành chẩn đoán và điều trị bệnh động mạch vành, Quyết định 5332/QĐ-BYT ngày 23 tháng 12 năm 2020 của Bộ Y tế.
3. Đỗ Châu Lan Hương (2019), Nghiên cứu tình hình rối loạn nhịp tim và đánh giá kết quả điều trị ngoại tâm thu thất ở bệnh nhân nhồi máu cơ tim cấp tại Bệnh viện Tim mạch An Giang năm 2018 – 2019, Luận văn Chuyên khoa cấp II, Trường Đại học Y Dược Cần Thơ.
4. Nguyễn Văn Tân, Nguyễn Văn Trí (2013), “Nghiên cứu đặc điểm lâm sàng ở bệnh nhân nhồi máu cơ tim cấp trên và dưới 65 tuổi”, Tạp chí Y học Tp.Hồ Chí Minh, phụ bản của tập 17(3), tr. 203-209.
5. Nguyễn Thắng (2019), Nghiên cứu đánh giá các vấn đề liên quan đến thuốc trong kê đơn cho bệnh nhân bệnh mạch vành được điều trị ngoại trú tại Bệnh viện Trường Đại học Y Dược Cần Thơ năm 2018 – 2019, Đề tài nghiên cứu khoa học cấp trường, Trường Đại học Y Dược Cần Thơ.
6. Ahn JH, Ahn Y, Jeong MH, Kim JH, Hong YJ, et al. (2020), Ticagrelor versus clopidogrel in acute myocardial infarction patients with multivessel disease; From Korea Acute Myocardial Infarction Registry-National Institute of Health, J Cardiol, 75(5),478-484.
7. Guan W, Lu H, Yang K (2017), Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention: A systematic review and Meta-Analysis (2007-2017), Medicine (Baltimore), 97(43).
8. Gulizia M. M., Colivicchi F., Abrignani M. G., Ambrosetti, M., Aspromonte, et al. (2018), Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease, European heart journal supplements : journal of the European Society of Cardiology, 1–74.
9. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E (2020), 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes, European Heart Journal, 00, 1-71.